Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AORT

AORT - Artivion, Inc. Stock Price, Fair Value and News

19.30USD+0.60 (+3.21%)Delayed as of 21 Feb 2024, 01:59 pm ET
Watchlist

Market Summary

USD19.30+0.60
Delayedas of 21 Feb 2024, 01:59 pm
3.21%

AORT Stock Price

View Fullscreen

AORT RSI Chart

AORT Valuation

Market Cap

767.6M

Price/Earnings (Trailing)

-31.27

Price/Sales (Trailing)

2.26

EV/EBITDA

34.7

Price/Free Cashflow

4.4K

AORT Price/Sales (Trailing)

AORT Profitability

EBT Margin

-5.22%

Return on Equity

-9.03%

Return on Assets

-3.17%

Free Cashflow Yield

0.02%

AORT Fundamentals

AORT Revenue

Revenue (TTM)

339.7M

Rev. Growth (Yr)

14.34%

Rev. Growth (Qtr)

-1.57%

AORT Earnings

Earnings (TTM)

-24.5M

Earnings Growth (Yr)

28.53%

Earnings Growth (Qtr)

-189.8%

Breaking Down AORT Revenue

52 Week Range

11.4419.37
(Low)(High)

Last 7 days

9.6%

Last 30 days

2.5%

Last 90 days

37.4%

Trailing 12 Months

40.5%

How does AORT drawdown profile look like?

AORT Financial Health

Current Ratio

4.86

Debt/Equity

1.12

Debt/Cashflow

0.03

AORT Investor Care

Shares Dilution (1Y)

1.78%

Diluted EPS (TTM)

-0.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023319.8M328.7M339.7M0
2022305.0M309.2M313.8M313.8M
2021257.9M280.3M287.3M298.8M
2020275.1M257.8M255.0M253.2M
2019268.4M271.0M274.3M276.2M
2018206.6M227.3M247.9M262.8M
2017182.4M183.2M181.9M189.7M
2016155.1M166.6M175.2M180.4M
2015142.7M143.6M143.2M145.9M
2014141.0M142.1M142.9M144.6M
2013135.0M135.3M138.1M140.8M
2012121.7M125.5M129.3M131.7M
2011117.1M117.2M118.5M119.6M
2010112.9M114.2M115.4M116.6M
2009000111.7M

Tracking the Latest Insider Buys and Sells of Artivion, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 02, 2024
davis john e
sold
-244,116
18.00
-13,562
senior vp, global sales
Jan 02, 2024
holloway jean f
sold
-382,122
18.00
-21,229
svp, general counsel
Jan 02, 2024
davis john e
acquired
221,061
16.3
13,562
senior vp, global sales
Jan 02, 2024
holloway jean f
acquired
346,033
16.3
21,229
svp, general counsel
Dec 31, 2023
holloway jean f
acquired
6,896
14.6115
472
svp, general counsel
Dec 31, 2023
stanton marshall s.
acquired
8,255
14.6115
565
svp, clinical & md affair
Dec 15, 2023
horton amy
sold
-273,543
19.00
-14,397
vp, chief accounting officer
Dec 15, 2023
horton amy
acquired
234,671
16.3
14,397
vp, chief accounting officer
Dec 06, 2023
berry lance a
acquired
750,001
17.83
42,064
executive vp, cfo
Dec 06, 2023
horton amy
acquired
360,006
17.83
20,191
vp, chief accounting officer

1–10 of 50

Which funds bought or sold AORT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-59.45
-652,000
598,000
0.05%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-14.49
5,000
574,000
-%
Feb 15, 2024
State of Wyoming
added
14.35
12,043
46,577
0.01%
Feb 15, 2024
Farther Finance Advisors, LLC
added
95.00
394
697
-%
Feb 15, 2024
Legal & General Group Plc
added
56.57
1,439,690
3,140,230
-%
Feb 15, 2024
BARCLAYS PLC
added
185
826,000
1,174,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-54.65
-230,594
265,214
-%
Feb 14, 2024
AMUNDI
unchanged
-
21,923
88,893
-%
Feb 14, 2024
TWO SIGMA INVESTMENTS, LP
added
51.77
565,591
1,281,570
-%
Feb 14, 2024
Public Sector Pension Investment Board
added
67.94
716,481
1,447,010
0.01%

1–10 of 42

Are Funds Buying or Selling AORT?

Are funds buying AORT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AORT
No. of Funds

Unveiling Artivion, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
macquarie group ltd
7%
2,873,431
SC 13G/A
Feb 13, 2024
vanguard group inc
6.41%
2,630,873
SC 13G/A
Feb 12, 2024
morgan stanley
5.8%
2,375,713
SC 13G/A
Feb 08, 2024
wellington management group llp
5.99%
2,459,646
SC 13G/A
Jan 22, 2024
blackrock inc.
16.7%
6,844,308
SC 13G/A
Feb 14, 2023
macquarie group ltd
6.60%
2,662,637
SC 13G/A
Feb 10, 2023
wasatch advisors inc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
6.97%
2,809,140
SC 13G/A
Feb 08, 2023
morgan stanley
5.4%
2,189,557
SC 13G
Feb 06, 2023
wellington management group llp
5.64%
2,275,255
SC 13G

Recent SEC filings of Artivion, Inc.

View All Filings
Date Filed Form Type Document
Feb 20, 2024
144
Notice of Insider Sale Intent
Feb 15, 2024
144
Notice of Insider Sale Intent
Feb 15, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
SC 13G/A
Major Ownership Report
Feb 08, 2024
SC 13G/A
Major Ownership Report
Jan 30, 2024
5
Insider Trading
Jan 30, 2024
5
Insider Trading
Jan 30, 2024
5
Insider Trading

What is the Fair Value of AORT?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Artivion, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
203.0B
40.1B
0.08% 5.41%
35.47
5.06
-8.12% -17.45%
69.5B
19.5B
1.90% -2.48%
55.36
3.57
4.02% -22.04%
24.0B
3.8B
13.67% -2.23%
66.19
6.31
-1.48% -28.97%
21.2B
14.9B
3.05% 1.38%
7.99
1.42
2.01% 209.17%
MID-CAP
10.1B
2.7B
6.89% -27.73%
-15.83
3.78
-4.68% 82.43%
9.8B
12.7B
2.56% -12.12%
22.09
0.77
0.68% -30.25%
9.2B
3.5B
8.76% 25.90%
32.42
2.64
4.97% 18.89%
7.2B
3.9B
-8.15% -6.44%
-32.65
1.82
-2.62% 73.16%
3.4B
342.6M
-1.40% 20.18%
-286.99
10.05
42.19% 84.12%
2.6B
6.6B
-4.32% -4.67%
13.17
0.4
2.61% 0.52%
SMALL-CAP
987.5M
3.1B
8.08% -63.68%
-2.32
0.32
7.95% -543.98%
355.0M
163.3M
8.18% -20.52%
-14.45
2.17
7.14% -56.09%
241.9M
329.5M
3.17% -52.24%
-17.14
0.73
0.49% 64.22%
74.8M
50.3M
4.50% -30.54%
-4.94
1.49
3.23% 20.81%
4.3M
3.7M
-15.66% 215.09%
-0.35
1.15
5.77% 8.23%

Artivion, Inc. News

Latest updates
MarketBeat17 Feb 202402:22 am
Seeking Alpha16 Feb 202401:22 am
Yahoo Finance15 Feb 202410:35 pm
Stock Traders Daily.com3 months ago

Artivion, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-1.6%88.0089.0083.0079.0077.0080.0077.0079.0072.0076.0071.0068.0065.0054.0066.0070.0068.0071.0068.0068.0065.00
Gross Profit-3.1%56.0058.0054.0051.0049.0052.0051.0051.0048.0051.0048.0045.0043.0036.0044.0047.0045.0047.0044.0045.0043.00
Operating Expenses-11.1%58.0065.0058.0047.0053.0048.0049.0061.0049.0049.0046.0043.0039.0038.0045.0043.0041.0040.0042.0042.0038.00
  S&GA Expenses-10.7%51.0057.0050.0038.0041.0039.0039.0051.0039.0041.0039.0036.0034.0032.0039.0038.0034.0035.0037.0036.0033.00
  R&D Expenses-13.4%6.007.007.008.0012.009.0010.009.0010.008.008.007.006.006.006.005.006.006.006.007.005.00
EBITDA Margin17.3%0.09*0.07*0.07*0.08*0.02*0.08*0.09*0.09*0.15*0.10*0.10*0.08*---------
Interest Expenses3.9%7.006.006.005.005.004.004.004.004.00------------
Income Taxes-47.3%0.001.005.001.001.001.001.004.00-2.640.00-1.363.00-1.31-1.08-1.472.00-0.86-0.09-1.35-0.681.00
Earnings Before Taxes-254.5%-9.42-2.66-8.923.00-12.53-3.30-2.43-16.098.00-2.18-4.50-0.09-4.18-4.77-8.132.00-0.993.00-1.65-1.462.00
EBT Margin17.7%-0.05*-0.06*-0.07*-0.05*-0.11*-0.04*-0.04*-0.05*0.00*-0.04*-0.05*-0.07*---------
Net Income-189.8%-9.80-3.38-13.532.00-13.71-4.26-3.39-20.1011.00-2.18-3.14-3.46-2.87-3.69-6.66-0.68-0.133.00-0.30-0.782.00
Net Income Margin16.5%-0.07*-0.09*-0.09*-0.06*-0.13*-0.06*-0.05*-0.05*0.01*-0.04*-0.05*-0.07*---------
Free Cashflow12.5%6.005.00-8.39-2.311.00-10.13-2.84-1.85-6.18-3.10-4.543.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-0.4%775778757763743765782793819810795789782693621606593597587571570
  Current Assets1.2%267264241247238240245248257238236235234287214187181189179179174
    Cash Equivalents9.6%53.0049.0031.0039.0038.0040.0051.0055.0065.0051.0057.0062.0065.0012664.0034.0037.0040.0041.0042.0035.00
  Inventory0.4%79.0078.0076.0074.0073.0074.0076.0077.0078.0076.0073.0073.0069.0063.0054.0053.0048.0045.0044.0045.0046.00
  Net PPE-2.5%37.0038.0039.0039.0036.0036.0037.0038.0037.0036.0031.0033.0032.0032.0032.0032.0030.0031.0030.0031.0032.00
  Goodwill-1.1%243246246244235241248250252255254260254186184187183188187189188
Liabilities1.5%503495477478488483484492507509498461456397344320315315314296293
  Current Liabilities-2.3%55.0056.0044.0050.0046.0042.0043.0045.0061.0059.0058.0060.0054.0049.0044.0045.0042.0037.0036.0035.0031.00
  Long Term Debt-0.1%306306306306307307307307308308310290290289244215215215215216217
    LT Debt, Current-0.6%2.002.002.002.002.002.002.002.002.002.001.001.001.001.001.001.001.001.001.001.001.00
    LT Debt, Non Current-0.1%306306306306307307307307308308310290290289244215215215215216217
Shareholder's Equity-3.7%272283280284255282297301312302297329326297277286278282273275277
  Retained Earnings-28.7%-43.93-34.13-30.75-17.22-19.39-5.67-1.412.0022.0011.0014.0020.0023.0026.0030.0037.0037.0038.0035.0035.0036.00
  Additional Paid-In Capital1.2%351347343337334330327323309305301316316293274272269266262260259
Accumulated Depreciation------------78.00---71.00---65.00-
Shares Outstanding0.2%43.0042.0042.0042.0040.0040.0040.0039.0039.0039.0039.0038.00---------
Float------725---1,070---694---1,078---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations4.7%7,2326,909-6,154-2173,976-8,314-598716-2,9092,647-3,0395,4507,679-3,3952,6351,06012,8607461,16110,5218,320
  Share Based Compensation-19.1%3,1873,9383,3413,1553,0892,9343,1663,2402,8762,1152,480-5202,3582,5102,5642,2182,4622,2691,8501,6401,568
Cashflow From Investing-129.2%-2,0687,078-2,843-2,668-3,053-2,286-2,708-2,81215,516-6,234-810-2,346-66,301-1,578-2,903-3,190-17,107-2,219-1,427-1,718-1,366
Cashflow From Financing-140.7%-9092,2331,171-859252-797-235-8,801315-1,642-2,095-1,682-89667,67128,515-657-12.00391-1,215-1,2841,682

AORT Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Total revenues$ 87,854$ 76,838$ 260,334$ 234,391
Cost of products and preservation services:    
Total cost of products and preservation services31,58428,09492,25382,756
Gross margin56,27048,744168,081151,635
Operating expenses:    
General, administrative, and marketing51,09341,051158,699118,989
Research and development6,42111,79921,06230,575
Total operating expenses57,51452,850179,761149,564
Gain from sale of non-financial assets00(14,250)0
Operating (loss) income(1,244)(4,106)2,5702,071
Interest expense6,6034,80519,05512,854
Interest income(339)(40)(679)(86)
Other expense, net1,9113,6615,1897,564
Loss before income taxes(9,419)(12,532)(20,995)(18,261)
Income tax expense3821,1815,7203,100
Net loss$ (9,801)$ (13,713)$ (26,715)$ (21,361)
Loss per share:    
Basic (in usd per share)$ (0.24)$ (0.34)$ (0.65)$ (0.53)
Diluted (in usd per share)$ (0.24)$ (0.34)$ (0.65)$ (0.53)
Weighted-average common shares outstanding:    
Basic (in shares)40,88140,11540,69139,999
Diluted (in shares)40,88140,11540,69139,999
Net loss$ (9,801)$ (13,713)$ (26,715)$ (21,361)
Other comprehensive loss:    
Foreign currency translation adjustments(5,010)(16,895)432(35,466)
Comprehensive loss(14,811)(30,608)(26,283)(56,827)
Products    
Revenues:    
Total revenues63,74755,248192,041171,726
Cost of products and preservation services:    
Total cost of products and preservation services21,57417,74362,08453,381
Preservation services    
Revenues:    
Total revenues24,10721,59068,29362,665
Cost of products and preservation services:    
Total cost of products and preservation services$ 10,010$ 10,351$ 30,169$ 29,375

AORT Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 53,481$ 39,351
Trade receivables, net64,27761,820
Other receivables3,9937,764
Inventories, net78,79274,478
Deferred preservation costs, net49,39146,371
Prepaid expenses and other17,17517,550
Total current assets267,109247,334
Goodwill242,936243,631
Acquired technology, net142,675151,263
Operating lease right-of-use assets, net43,34541,859
Property and equipment, net37,42838,674
Other intangibles, net29,39831,384
Deferred income taxes3,7051,314
Other assets8,1917,339
Total assets774,787762,798
Current liabilities:  
Accounts payable10,81912,004
Accrued compensation13,86113,810
Accrued expenses9,93012,374
Taxes payable9,3902,635
Current maturities of operating leases3,9403,308
Accrued procurement fees1,8602,111
Current portion of long-term debt1,5521,608
Other liabilities3,6071,825
Total current liabilities54,95949,675
Long-term debt305,877306,499
Contingent consideration62,30040,400
Non-current maturities of operating leases42,86241,257
Deferred income taxes19,51424,499
Deferred compensation liability6,4605,468
Non-current finance lease obligation3,2723,644
Other liabilities7,5687,027
Total liabilities502,812478,469
Commitments and contingencies
Shareholders' equity:  
Preferred stock00
Common stock (75,000 shares authorized, 42,537 and 41,830 shares issued and outstanding in 2023 and 2022, respectively)425418
Additional paid-in capital351,307337,385
Retained deficit(43,932)(17,217)
Accumulated other comprehensive loss(21,177)(21,609)
Treasury stock, at cost, 1,487 shares as of September 30, 2023 ‎and December 31, 2022(14,648)(14,648)
Total shareholders' equity271,975284,329
Total liabilities and shareholders' equity$ 774,787$ 762,798
AORT
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent and graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
 CEO
 WEBSITEartivion.com
 EMPLOYEES1300

Artivion, Inc. Frequently Asked Questions


What is the ticker symbol for Artivion, Inc.? What does AORT stand for in stocks?

AORT is the stock ticker symbol of Artivion, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Artivion, Inc. (AORT)?

As of Tue Feb 20 2024, market cap of Artivion, Inc. is 767.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AORT stock?

You can check AORT's fair value in chart for subscribers.

What is the fair value of AORT stock?

You can check AORT's fair value in chart for subscribers. The fair value of Artivion, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Artivion, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AORT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Artivion, Inc. a good stock to buy?

The fair value guage provides a quick view whether AORT is over valued or under valued. Whether Artivion, Inc. is cheap or expensive depends on the assumptions which impact Artivion, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AORT.

What is Artivion, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 20 2024, AORT's PE ratio (Price to Earnings) is -31.27 and Price to Sales (PS) ratio is 2.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AORT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Artivion, Inc.'s stock?

In the past 10 years, Artivion, Inc. has provided 0.066 (multiply by 100 for percentage) rate of return.